Pharmacokinetic/pharmacodynamic data extrapolation models for improved pediatric efficacy and toxicity estimation, with application to secondary hyperparathyroidism-Reference-Cited by-同舟云学术

Pharmacokinetic/pharmacodynamic data extrapolation models for improved pediatric efficacy and toxicity estimation, with application to secondary hyperparathyroidism

Published:2020-07-09 Issue:6 Volume:19 Page:882-896
ISSN:1539-1604
Container-title:Pharmaceutical Statistics
language:en
Short-container-title:Pharmaceutical Statistics

Author:

Basu Cynthia¹^ORCID,Ma Xiaoye²,Mo May³,Xia Hong Amy³,Brundage Richard⁴,Al‐Kofahi Mahmoud⁴,Carlin Bradley P.⁵

Affiliation:

1. Pfizer Inc. San Diego California USA

2. Genentech Inc. San Francisco California USA

3. Amgen Inc. Thousand Oaks California USA

4. Department of Experimental and Clinical Pharmacology College of Pharmacy, University of Minnesota Minneapolis Minnesota USA

5. Counterpoint Statistical Consulting, LLC Edina Minnesota USA

Funder

Amgen

Center for Strategic Scientific Initiatives, National Cancer Institute

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology,Statistics and Probability

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pst.2043

Reference50 articles.

1. Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics

2. Sensipar.http://www.sensipar.com/about-sensipar/how-sensipar-works.html. Accessed June 28 2017.

3. Tricking the parathyroid gland with novel calcimimetic agents

4. Pharmacodynamics of the Type II Calcimimetic Compound Cinacalcet HCl

5. Clinical trials in children

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bayesian Complex Innovative Trial Designs (CIDs) and Their Use in Drug Development for Rare Disease;The Journal of Clinical Pharmacology;2022-12